PURPOSE: Amplification and high levels of NOTCH ligand expression have been identified in several types of pediatric brain tumors. A phase I trial of weekly MK-0752, an oral inhibitor of gamma-secretase, was conducted in children with recurrent central nervous system (CNS) malignancies to estimate the maximum tolerated dose, dose-limiting toxicities (DLT), pharmacokinetics (PK), and pharmacodynamics of weekly MK-0752. METHODS: MK-0752 was administered once weekly at 1000 and 1400 mg/m(2) using a rolling-6 design. PK analysis was performed during the first course. NOTCH and HES expression was assessed by immunohistochemistry and Western blot. RESULTS: Ten eligible patients were enrolled (median age 8.8 years; range 3.1-19.2) with diagnoses of brain stem glioma (n = 3), ependymoma (n = 2), anaplastic astrocytoma (n = 1), choroid plexus carcinoma (n = 2), medulloblastoma (n = 1), and primitive neuroectodermal tumor (n = 1). Nine were evaluable for toxicity. One DLT of fatigue occurred in the six evaluable patients enrolled at 1000 mg/m(2)/dose. No DLTs were experienced by three patients treated at 1400 mg/m(2)/dose. Non-dose-limiting grade 3 toxicities included lymphopenia, neutropenia, and anemia. Median number of treatment courses was 2 (range 1-10). Two patients continued on therapy for at least 6 months. The median (range) C(max) of MK-0752 was 88.2 μg/mL (40.6 to 109 μg/mL) and 60.3 μg/mL (59.2 to 91.9 μg/mL) in patients receiving 1000 and 1400 mg/m(2)/week, respectively. NOTCH expression was decreased in six of seven patients for whom tissue was available at 24 h post-MK-0752. CONCLUSION: MK-0752 is well tolerated and exhibits target inhibition at 1000 and 1400 mg/m(2)/week in children with recurrent CNS malignancies.
PURPOSE: Amplification and high levels of NOTCH ligand expression have been identified in several types of pediatric brain tumors. A phase I trial of weekly MK-0752, an oral inhibitor of gamma-secretase, was conducted in children with recurrent central nervous system (CNS) malignancies to estimate the maximum tolerated dose, dose-limiting toxicities (DLT), pharmacokinetics (PK), and pharmacodynamics of weekly MK-0752. METHODS:MK-0752 was administered once weekly at 1000 and 1400 mg/m(2) using a rolling-6 design. PK analysis was performed during the first course. NOTCH and HES expression was assessed by immunohistochemistry and Western blot. RESULTS: Ten eligible patients were enrolled (median age 8.8 years; range 3.1-19.2) with diagnoses of brain stem glioma (n = 3), ependymoma (n = 2), anaplastic astrocytoma (n = 1), choroid plexus carcinoma (n = 2), medulloblastoma (n = 1), and primitive neuroectodermal tumor (n = 1). Nine were evaluable for toxicity. One DLT of fatigue occurred in the six evaluable patients enrolled at 1000 mg/m(2)/dose. No DLTs were experienced by three patients treated at 1400 mg/m(2)/dose. Non-dose-limiting grade 3 toxicities included lymphopenia, neutropenia, and anemia. Median number of treatment courses was 2 (range 1-10). Two patients continued on therapy for at least 6 months. The median (range) C(max) of MK-0752 was 88.2 μg/mL (40.6 to 109 μg/mL) and 60.3 μg/mL (59.2 to 91.9 μg/mL) in patients receiving 1000 and 1400 mg/m(2)/week, respectively. NOTCH expression was decreased in six of seven patients for whom tissue was available at 24 h post-MK-0752. CONCLUSION:MK-0752 is well tolerated and exhibits target inhibition at 1000 and 1400 mg/m(2)/week in children with recurrent CNS malignancies.
Authors: Ileana C Cuevas; Alison L Slocum; Peter Jun; Joseph F Costello; Andrew W Bollen; Gregory J Riggins; Michael W McDermott; Anita Lal Journal: Cancer Res Date: 2005-06-15 Impact factor: 12.701
Authors: Ian Krop; Tim Demuth; Tina Guthrie; Patrick Y Wen; Warren P Mason; Prakash Chinnaiyan; Nicholas Butowski; Morris D Groves; Santosh Kesari; Steven J Freedman; Samuel Blackman; James Watters; Andrey Loboda; Alexei Podtelezhnikov; Jared Lunceford; Cong Chen; Maxine Giannotti; Jeremy Hing; Robert Beckman; Patricia Lorusso Journal: J Clin Oncol Date: 2012-04-30 Impact factor: 44.544
Authors: Giovanni Tonon; Sanjay Modi; Lizi Wu; Akihito Kubo; Amy B Coxon; Takefumi Komiya; Kevin O'Neil; Kristen Stover; Adel El-Naggar; James D Griffin; Ilan R Kirsch; Frederic J Kaye Journal: Nat Genet Date: 2003-01-21 Impact factor: 38.330
Authors: Tatyana N Ignatova; Valery G Kukekov; Eric D Laywell; Oleg N Suslov; Frank D Vrionis; Dennis A Steindler Journal: Glia Date: 2002-09 Impact factor: 7.452
Authors: Maryam Fouladi; Fred Laningham; Jianrong Wu; Melinda A O'Shaughnessy; Kristen Molina; Alberto Broniscer; Sheri L Spunt; Inga Luckett; Clinton F Stewart; Peter J Houghton; Richard J Gilbertson; Wayne L Furman Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: Maryam Fouladi; John P Perentesis; Christine L Phillips; Sarah Leary; Joel M Reid; Renee M McGovern; Ashish M Ingle; Charlotte H Ahern; Matthew M Ames; Peter Houghton; L Austin Doyle; Brenda Weigel; Susan M Blaney Journal: Pediatr Blood Cancer Date: 2014-03-24 Impact factor: 3.167
Authors: Tyler R McCaw; Evelyn Inga; Herbert Chen; Renata Jaskula-Sztul; Vikas Dudeja; James A Bibb; Bin Ren; J Bart Rose Journal: Oncologist Date: 2021-01-02
Authors: Francisco Bautista; Victoria Fioravantti; Teresa de Rojas; Fernando Carceller; Luis Madero; Alvaro Lassaletta; Lucas Moreno Journal: Cancer Med Date: 2017-10-04 Impact factor: 4.452